Downloads: 1
308 lines (307 with data), 10.0 kB
T1 Date 0 7 In 2013 E1 Date:T1 T2 Age 11 22 50-year-old T3 Sex 23 26 man T4 Clinical_event 35 42 visited E2 Clinical_event:T4 T5 Nonbiological_location 43 51 hospital T6 Sign_symptom 78 82 pain E3 Sign_symptom:T6 T7 Biological_structure 73 77 bone T8 Biological_structure 90 98 left leg T9 Detailed_description 67 72 local R1 MODIFY Arg1:T8 Arg2:E3 R2 MODIFY Arg1:T7 Arg2:E3 R3 MODIFY Arg1:T9 Arg2:E3 T10 Date 103 118 August 14, 2013 E4 Date:T10 T11 Disease_disorder 292 304 osteosarcoma E5 Disease_disorder:T11 T12 Detailed_description 279 291 osteoblastic R4 MODIFY Arg1:T12 Arg2:E5 T13 Therapeutic_procedure 178 187 resection E6 Therapeutic_procedure:T13 T14 Detailed_description 170 177 en bloc R5 MODIFY Arg1:T14 Arg2:E6 T15 Sign_symptom 164 169 tumor E7 Sign_symptom:T15 T16 Biological_structure 144 163 left distal femoral R6 MODIFY Arg1:T16 Arg2:E7 T17 Therapeutic_procedure 192 206 reconstruction E8 Therapeutic_procedure:T17 T18 Detailed_description 214 247 modular femoral prosthetic system R7 MODIFY Arg1:T18 Arg2:E8 T19 Diagnostic_procedure 249 268 Pathology diagnosis E9 Diagnostic_procedure:T19 T20 Medication 339 351 chemotherapy E10 Medication:T20 T21 Detailed_description 327 338 neoadjuvant R8 MODIFY Arg1:T21 Arg2:E10 T22 Dosage 314 323 One cycle R9 MODIFY Arg1:T22 Arg2:E10 T23 Dosage 356 364 4 cycles T24 Detailed_description 368 376 adjuvant T25 Medication 377 389 chemotherapy E11 Medication:T25 R10 MODIFY Arg1:T24 Arg2:E11 R11 MODIFY Arg1:T23 Arg2:E11 T26 Medication 395 406 MAP regimen E12 Medication:T26 T27 Medication 418 430 methotrexate E13 Medication:T27 T28 Dosage 408 417 high-dose R12 MODIFY Arg1:T28 Arg2:E13 R13 SUB_PROCEDURE Arg1:E13 Arg2:E12 T29 Medication 432 441 cisplatin E14 Medication:T29 T30 Medication 447 458 doxorubicin E15 Medication:T30 R14 SUB_PROCEDURE Arg1:E14 Arg2:E12 R15 SUB_PROCEDURE Arg1:E15 Arg2:E12 T31 Date 482 494 January 2015 E16 Date:T31 T32 Sign_symptom 498 502 mass E17 Sign_symptom:T32 T33 Biological_structure 520 540 left upper crus area R16 MODIFY Arg1:T33 Arg2:E17 T34 Sign_symptom 548 558 recurrence E18 Sign_symptom:T34 T35 Diagnostic_procedure 576 582 biopsy E19 Diagnostic_procedure:T35 T36 Date 586 602 January 23, 2015 E20 Date:T36 T37 Therapeutic_procedure 633 643 amputation E21 Therapeutic_procedure:T37 T38 Biological_structure 621 632 upper femur R17 MODIFY Arg1:T38 Arg2:E21 T39 Therapeutic_procedure 688 705 joint replacement E22 Therapeutic_procedure:T39 A1 POLARITY E22 NEG T40 Biological_structure 684 687 hip R18 MODIFY Arg1:T40 Arg2:E22 T41 Therapeutic_procedure 713 726 wound healing E23 Therapeutic_procedure:T41 T42 Clinical_event 740 768 went back to his normal life E24 Clinical_event:T42 T44 Therapeutic_procedure 784 799 artificial limb E25 Therapeutic_procedure:T44 #1 AnnotatorNotes E25 not a therapy per se T45 Medication 832 844 chemotherapy E26 Medication:T45 A2 POLARITY E26 NEG T46 Date 967 984 half a year after E27 Date:T46 T47 Sign_symptom 1028 1033 cough E28 Sign_symptom:T47 T48 Sign_symptom 1044 1053 tightness E29 Sign_symptom:T48 T49 Biological_structure 1038 1043 chest T50 Detailed_description 1017 1027 occasional R20 MODIFY Arg1:T50 Arg2:E28 R21 MODIFY Arg1:T49 Arg2:E29 T51 Diagnostic_procedure 1073 1092 computed tomography E30 Diagnostic_procedure:T51 T52 Diagnostic_procedure 1094 1096 CT E31 Diagnostic_procedure:T52 T53 Biological_structure 1067 1072 chest T54 Detailed_description 1062 1066 thin R22 MODIFY Arg1:T53 Arg2:E30 R23 MODIFY Arg1:T54 Arg2:E30 R24 IDENTICAL Arg1:E31 Arg2:E30 T55 Date 1115 1128 July 15, 2015 E32 Date:T55 T56 Sign_symptom 1173 1180 nodules E33 Sign_symptom:T56 T57 Biological_structure 1163 1172 pulmonary T58 Detailed_description 1154 1162 multiple R25 MODIFY Arg1:T57 Arg2:E33 R26 MODIFY Arg1:T58 Arg2:E33 T59 Sign_symptom 1224 1234 metastases E34 Sign_symptom:T59 A3 POLARITY E34 UNCERTAIN T60 Medication 1271 1283 chemotherapy E35 Medication:T60 A4 POLARITY E35 NEG T61 Diagnostic_procedure 1285 1300 Immunophenotype E36 Diagnostic_procedure:T61 T62 Sign_symptom 1335 1340 tumor E37 Sign_symptom:T62 T63 Detailed_description 1329 1334 CD34+ T64 Detailed_description 1319 1324 CD31+ R27 MODIFY Arg1:T63 Arg2:E37 R28 MODIFY Arg1:T64 Arg2:E37 T65 Coreference 1374 1379 cells E38 Coreference:T65 R29 IDENTICAL Arg1:E38 Arg2:E37 T66 Diagnostic_procedure 1403 1423 staining for VEGFR-2 E39 Diagnostic_procedure:T66 T67 Lab_value 1387 1402 strong positive R30 MODIFY Arg1:T67 Arg2:E39 R31 MODIFY Arg1:E38 Arg2:E39 T68 Medication 1433 1441 Apatinib E40 Medication:T68 T69 Dosage 1472 1484 500 mg daily R32 MODIFY Arg1:T69 Arg2:E40 T70 Activity 3025 3032 driving E41 Activity:T70 T71 Date 1486 1504 Half a month later E42 Date:T71 T72 Sign_symptom 1510 1518 symptoms E43 Sign_symptom:T72 A5 POLARITY E43 NEG T73 Sign_symptom 1550 1564 wound necrosis E44 Sign_symptom:T73 T74 Detailed_description 1538 1549 progressive R33 MODIFY Arg1:T74 Arg2:E44 T75 Therapeutic_procedure 1577 1596 debridement surgery E45 Therapeutic_procedure:T75 T76 Therapeutic_procedure 1669 1677 resected E46 Therapeutic_procedure:T76 T77 Sign_symptom 1626 1634 enlarged E47 Sign_symptom:T77 T78 Biological_structure 1635 1645 lymph node R34 MODIFY Arg1:T78 Arg2:E47 T79 Biological_structure 1646 1664 near iliac vessels R35 MODIFY Arg1:T79 Arg2:T78 T80 Date 1681 1698 February 24, 2016 E48 Date:T80 R36 MODIFY Arg1:T78 Arg2:E46 T81 Diagnostic_procedure 1730 1754 pathological examination E49 Diagnostic_procedure:T81 T82 Sign_symptom 1780 1791 hyperplasia E50 Sign_symptom:T82 T83 Detailed_description 1767 1779 inflammatory R37 MODIFY Arg1:T83 Arg2:E50 T84 Biological_structure 1792 1802 lymph node R38 MODIFY Arg1:T84 Arg2:E50 T85 Medication 1804 1812 Apatinib E51 Medication:T85 A6 POLARITY E51 NEG T86 Duration 1851 1858 3 weeks E52 Duration:T86 T87 Therapeutic_procedure 1862 1875 wound healing E53 Therapeutic_procedure:T87 T88 Diagnostic_procedure 1899 1901 CT E54 Diagnostic_procedure:T88 T89 Biological_structure 1893 1898 chest T90 Detailed_description 1888 1892 thin R39 MODIFY Arg1:T89 Arg2:E54 R40 MODIFY Arg1:T90 Arg2:E54 T91 Date 1916 1931 7 and 11 months E55 Date:T91 T92 Clinical_event 1982 1991 follow-up E56 Clinical_event:T92 T93 Date 1974 1981 7-month E57 Date:T93 T94 Lab_value 2658 2660 PR #2 AnnotatorNotes T94 partial response T95 Diagnostic_procedure 2581 2592 measurement E58 Diagnostic_procedure:T95 T96 Detailed_description 2574 2580 lesion R41 MODIFY Arg1:T96 Arg2:E58 T97 Diagnostic_procedure 2610 2629 RECIST 1.1 standard E59 Diagnostic_procedure:T97 R42 SUB_PROCEDURE Arg1:E59 Arg2:E58 R43 MODIFY Arg1:T94 Arg2:E59 T98 Disease_disorder 2715 2733 hand-foot syndrome E60 Disease_disorder:T98 T99 Severity 2710 2714 mild R44 MODIFY Arg1:T99 Arg2:E60 T100 Sign_symptom 2745 2764 high blood pressure E61 Sign_symptom:T100 T101 Severity 2738 2744 slight R45 MODIFY Arg1:T101 Arg2:E61 T102 Lab_value 2776 2819 well controlled after appropriate treatment R46 MODIFY Arg1:T102 Arg2:E60 R47 MODIFY Arg1:T102 Arg2:E61 T103 Sign_symptom 2831 2841 toxicities E62 Sign_symptom:T103 A7 POLARITY E62 NEG T104 Sign_symptom 2870 2884 adverse events E63 Sign_symptom:T104 A8 POLARITY E63 NEG T105 Severity 2824 2830 severe R48 MODIFY Arg1:T105 Arg2:E62 T106 Detailed_description 2852 2869 treatment-related R49 MODIFY Arg1:T106 Arg2:E63 T107 Medication 2929 2937 apatinib E64 Medication:T107 T108 Sign_symptom 2975 2988 toxic effects E65 Sign_symptom:T108 A9 POLARITY E65 NEG T109 Clinical_event 2994 3018 went back to normal life E66 Clinical_event:T109 T111 Detailed_description 3036 3049 automatic car #3 AnnotatorNotes T111 why is this relevant R51 MODIFY Arg1:T111 Arg2:E41 T112 Sign_symptom 2057 2064 lesions E67 Sign_symptom:T112 A10 POLARITY E67 NEG T113 Lab_value 2004 2025 2 out of 5 measurable T114 Lab_value 2030 2056 9 out of 17 non-measurable R52 MODIFY Arg1:T114 Arg2:E67 R53 MODIFY Arg1:T113 Arg2:E67 T115 Sign_symptom 2099 2105 nodule E68 Sign_symptom:T115 T116 Sign_symptom 2131 2138 lesions E69 Sign_symptom:T116 T117 Lab_value 2082 2098 1 new measurable R54 MODIFY Arg1:T117 Arg2:E68 T118 Lab_value 2110 2130 6 new non-measurable R55 MODIFY Arg1:T118 Arg2:E69 T119 Diagnostic_procedure 2209 2253 Response Evaluation Criteria in Solid Tumors E70 Diagnostic_procedure:T119 T120 Diagnostic_procedure 2255 2261 RECIST E71 Diagnostic_procedure:T120 R56 IDENTICAL Arg1:E71 Arg2:E70 T121 Detailed_description 2263 2266 1.1 R57 MODIFY Arg1:T121 Arg2:E70 T122 Lab_value 2189 2191 PD R58 MODIFY Arg1:T122 Arg2:E70 T123 Clinical_event 2302 2311 follow-up E72 Clinical_event:T123 T124 Date 2293 2301 11-month E73 Date:T124 T125 Sign_symptom 2337 2344 lesions E74 Sign_symptom:T125 A11 POLARITY E74 NEG T126 Lab_value 2335 2336 9 R59 MODIFY Arg1:T126 Arg2:E74 T127 Lab_value 2368 2387 1 measurable nodule R60 MODIFY Arg1:T127 Arg2:E74 T128 Lab_value 2392 2416 2 non-measurable lesions R61 MODIFY Arg1:T128 Arg2:E74 T129 Lab_value 2464 2489 6 non-measureable lesions R62 MODIFY Arg1:T129 Arg2:E74 R63 MODIFY Arg1:T5 Arg2:E2 * OVERLAP E1 E2 E3 R64 BEFORE Arg1:E3 Arg2:E4 * OVERLAP E4 E7 E6 E8 E9 E5 R65 BEFORE Arg1:E5 Arg2:E10 * OVERLAP E10 E11 E12 R66 BEFORE Arg1:E12 Arg2:E16 * OVERLAP E16 E17 R67 BEFORE Arg1:E17 Arg2:E18 * OVERLAP E18 E19 E20 R68 BEFORE Arg1:E20 Arg2:E21 * OVERLAP E21 E22 R69 BEFORE Arg1:E22 Arg2:E23 R70 BEFORE Arg1:E23 Arg2:E24 * OVERLAP E24 E25 E26 R71 BEFORE Arg1:E26 Arg2:E27 * OVERLAP E27 E28 E29 R72 BEFORE Arg1:E29 Arg2:E30 * OVERLAP E30 E32 E33 E34 E35 E36 E37 E38 E39 R73 BEFORE Arg1:E39 Arg2:E40 R74 BEFORE Arg1:E40 Arg2:E42 * OVERLAP E42 E43 E44 R75 BEFORE Arg1:E44 Arg2:E45 * OVERLAP E45 E47 E46 E48 E49 E50 R76 BEFORE Arg1:E50 Arg2:E51 * OVERLAP E51 E52 E53 R77 BEFORE Arg1:E53 Arg2:E54 * OVERLAP E54 E55 E57 E56 E67 E68 E69 E70 R78 BEFORE Arg1:E70 Arg2:E73 * OVERLAP E73 E72 E74 E58 E60 E61 E62 E63 R79 BEFORE Arg1:E63 Arg2:E64 * OVERLAP E64 E65 E66 E41